Drug Name: Krazati
Active Ingredient: adagrasib
Indications: To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy
Approval Date: 12/12/2022
Company: Mirati Therapeutics, Inc.
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf